Background We aimed to examine cemiplimab, a programmed cell death 1 inhibitor, in the
first-line treatment of advanced non-small-cell lung cancer with programmed cell death …

Background First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …

Purpose Nivolumab, a fully human immunoglobulin G4 programmed death-1 immune
checkpoint inhibitor antibody, has demonstrated improved survival in previously treated …

Introduction: Chemotherapeutic drugs are used in combination to target multiple
mechanisms involved in cancer cell survival and proliferation. Carriers are developed to …

Background Our prospective, open-label, single-arm phase II study investigated the safety
and efficacy of DCVAC/LuCa (dendritic cell vaccines for lung cancer) combined with …

Introduction Activation of the RAS/RAF/MEK/ERK pathway may confer resistance to
chemotherapy in non-small cell lung cancer (NSCLC). Selumetinib (AZD6244 …

Introduction To date, no prospective phase III trials have directly compared the efficacy of
pemetrexed plus cisplatin (Pem-Cis) with docetaxel plus cisplatin (Doc-Cis) in patients with …

Background Regimens combining pemetrexed (PEM) and immune checkpoint inhibitors
(ICIs) targeting programmed cell death-1 (PD-1) or programmed death-ligand 1 (PD-L1) are …

Methods A comprehensive search of related articles was performed focused on phases Ⅱ
and Ⅲ clinical trials studies. Results The lung cancer management should take into …

Background In a phase III study, maintenance pemetrexed showed superior survival over
placebo (PARAMOUNT) for patients with advanced non-squamous non-small cell lung …